Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry

20250 citationsJournal Article

Authors

Trung M. Dang · Albury Wodonga Health

Alessandro Invernizzi · The University of Sydney

Vuong Nguyen · The University of Sydney

Yohei Hashimoto · The University of Sydney

Francesco Romano · University of Milan

Mariano Cozzi · University of Milan

Jennifer Arnold ·

Abstract

Eyes that switched from a first generation VEGF inhibitor to brolucizumab in routine clinical practice achieved a clinically significant extension of their treatment interval, with more than a third becoming inactive but with a relatively high rate of IOI.

Topics & Keywords

Retinal Diseases and Treatments Ocular Diseases and Behçet’s Syndrome Retinopathy of Prematurity Studies

Publication Details

Published in: Clinical and Experimental Ophthalmology

Volume 54, Issue 2, pp. 233-240

DOI: 10.1111/ceo.70033

Field-Weighted Citation Impact: 0.00

Command Palette

Twelve‐Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry

Authors

Abstract

Topics & Keywords

Publication Details